The PROLASTIN DIRECT® program: Benefits beyond therapy
Comprehensive, personalized alpha-1 support for your patients
When you prescribe PROLASTIN-C LIQUID, your patients gain immediate access to all the benefits of the PROLASTIN DIRECT program. PROLASTIN-C LIQUID is available only through the PROLASTIN DIRECT program.
To help you get started, speak with a Patient Service Coordinator by calling 1-833-PHONEA1 (746-6321).
Have you tested your patients with COPD for alpha-1? If not, you can order your free AlphaID screening kits here.
The PROLASTIN DIRECT program simplifies alpha-1 management for you and your patients1
A dedicated PROLASTIN-C LIQUID coordinator1
Upon enrollment, you and your patients with alpha-1 will be assigned a dedicated PROLASTIN-C LIQUID coordinator to help with all needs related to alpha-1 treatment.1
PROLASTIN DIRECT insurance specialists1
PROLASTIN DIRECT insurance specialists, who have a >90% success rate in obtaining patient coverage, will provide hands-on management of the prior authorization process.1
Specialty pharmacy and infusion experts1
Your PROLASTIN DIRECT Alpha-1 Care Team's specialty pharmacy and infusion experts:
- 24/7 on-call support from specialty-trained registered nurses and pharmacists dedicated exclusively to alpha-1 care1
Automatic enrollment in a disease management program1
As part of the PROLASTIN DIRECT program, patients are automatically enrolled in a disease-management program (AlphaNet®) where they receive one-on-one support from a treatment-experienced patient with alpha-1.1
PROLASTIN-C LIQUID is available only throughthe PROLASTIN DIRECT program
Improving patient outcomes with the AlphaNet® disease-management program1,2
By enrolling your patients in the PROLASTIN DIRECT program, they are automatically connected to the AlphaNet Alpha-1 Disease Management and Prevention Program (ADMAPP).
ADMAPP is the only fully integrated disease-management program shown to improve patient outcomes.1,2*
Significant improvements in health outcomes after intervention year (n=878)2
Increase in the use of long-term oxygen therapy (>16 hours/day [P<0.01])2
- Translates into more optimal use of oxygen therapy
Increase in the use of long-acting bronchodilator (P<0.001)2
- Translates into more optimal medication use
Reduction in exacerbations (P<0.001)2
Reduction in unscheduled physician visits (P=0.03)2
Reduction in emergency room visits (P=0.02)2
Reduction in the use of systemic steroids (P=0.02)2
*Patient outcomes are based on a 2-year study comparing outcomes in a 12-month observation period with augmentation therapy alone and a 12-month intervention period with augmentation therapy plus ADMAPP2:
- Participants were members of AlphaNet®, a not-for-profit health management company founded by patients with alpha-1 to provide comprehensive care solely for patients with alpha-12
- 97% of ADMAPP study participants were taking PROLASTIN® (alpha1-proteinase inhibitor [human])2
Enroll your patients in the PROLASTIN DIRECT program
Simply download, complete, and fax the PROLASTIN DIRECT enrollment form.
IMPORTANT SAFETY INFORMATION
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
References:
1. Data on file, PROLASTIN DIRECT program. 2. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.